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Abstract
p63 is critical for squamous epithelial development, and elevated levels of the DNp63a isoform are seen in squamous cell
cancers of various organ sites. However, significant controversy exists regarding the role of p63 isoforms as oncoproteins or
tumor suppressors. Here, lentiviruses were developed to drive long-term overexpression of DNp63a in primary
keratinocytes. Elevated levels of DNp63a in vitro promote long-term survival and block both replicative and oncogene-
induced senescence in primary keratinocytes, as evidenced by the expression of SA-b-gal and the presence of nuclear foci of
heterochromatin protein 1c. The contribution of DNp63a to cancer development was assessed using an in vivo grafting
model of experimental skin tumorigenesis that allows distinction between benign and malignant tumors. Grafted lenti-
DNp63a keratinocytes do not form tumors, whereas lenti-GFP/v-ras
Ha keratinocytes develop well-differentiated papillomas.
Lenti-DNp63a/v-ras
Ha keratinocytes form undifferentiated carcinomas. The average volume of lenti-DNp63a/v-ras
Ha tumors
was significantly higher than those in the lenti-GFP/v-ras
Ha group, consistent with increased BrdU incorporation detected by
immunohistochemistry. The block in oncogene-induced senescence corresponds to sustained levels of E2F1 and
phosphorylated AKT, and is associated with loss of induction of p16
ink4a/p19
arf. The relevance of p16
ink4a/p19
arf loss was
demonstrated in grafting studies of p19
arf-null keratinocytes, which develop malignant carcinomas in the presence of v-
ras
Ha similar to those arising in wildtype keratinocytes that express lenti-DNp63a and v-ras
Ha. Our findings establish that
DNp63a has oncogenic activity and its overexpression in human squamous cell carcinomas contributes to the malignant
phenotype, and implicate its ability to regulate p16
ink4a/p19
arf in the process.
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Introduction
p63 is a p53 homologue. The p63 gene contains the three
functional domains homologous to those of p53, which mediate
transactivation (TA), DNA binding (DBD) and oligomerization
(OD) [1]. However, in contrast to p53’s well established role as a
tumor suppressor [2], p63 has been primarily considered a critical
developmental regulator of epithelium. It is well understood that
temporal regulation of individual p63 isoforms is required for both
normal development and maintenance of mature epidermis. This
is evidenced by studies in p63 null mice, which are born with
severe abnormalities, including the lack of epidermis and many
ectodermal derivatives, truncated limbs and craniofacial malfor-
mations [3,4] and further supported by studies of postnatal
keratinocytes in which p63 isoforms have been manipulated [5,6].
Despite similarities in their structures, p63 is also distinct
from p53 in its role in tumorigenesis. While p53 is one of the
most commonly mutated genes recognized to date in human
malignancies, p63 is rarely mutated in human cancers [7], though
p63 gene amplification and/or overexpression has been reported
in human squamous cell carcinomas (SCC) of the head and neck,
lung, cervix and skin [1,8–12].
p63 is further distinct from p53 in its role in cell senescence. It is
now well appreciated that senescence represents a potent
anticancer mechanism to prevent tumor progression from
premalignant to malignant lesions [13,14]. In contrast to p53’s
established role in promoting this tumor-suppressive machinery, it
has been shown that p63 deficiency leads to the activation of cell
senescence and accelerated aging in mice [15].
Significant controversy exists regarding the role of p63 as an
oncogene or as a tumor suppressor gene [7]. In a study by Flores
et al. [16], p63
+/2 mice were found to have increased susceptibility
to spontaneous tumorigenesis. A complex tumor phenotype was
observed in the mutant mice, which included squamous cell
carcinomas, histiocytic sarcomas and adenomas. Mice heterozy-
gous for null mutations in both p53 and p63 developed higher
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p63
+/+/p53
+/2 mice. These findings indicate that loss of p63 may
cooperate in tumor formation with p53 loss-of-function. In
contrast, an independent study by Keyes et al. [17] reported that
p63
+/2 mice were less prone to either spontaneous or chemically
induced tumors. The neoplasms that did develop in p63+/2 mice
included lymphomas, sarcomas and carcinomas. In the latter
study, mice heterozygous for null mutations in both p63 and p53
were found to have fewer tumors than p63
+/+/p53
+/2 mice. These
findings suggest that loss of p63 may prevent tumor formation
mediated by p53 loss-of-function.
The complexity of p63 contributes to the confusion surrounding
the role of p63 in tumorigenesis [7]. p63 protein may refer to
multiple variants arising from alternate promoter usage and/or
alternative splicing. The p63 gene is transcribed into two
subclasses, TA and DN, which differ at the amino-terminus [1].
Additionally, alternative splicing gives rise to COOH-terminal
variants p63a,- b and -c within both TA- and DN-subclasses.
TAp63 isoforms contain a p53-like N-terminal transactivation
(TA) domain and are capable of transactivating known p53-
responsive genes. DNp63 isoforms are transcribed from an
alternate promoter and lack this transactivation domain, while
still retaining transactivation activity [1,18–20]. DN isoforms have
also been shown to be capable of acting in a dominant-negative
manner to block transactivation mediated by TAp63 isoforms as
well as by p53 [1].
Accumulating evidence implies that the TA and DN isoforms
have distinct or even opposing functions in neoplasia. Although it
has been suggested that the tumor suppressor phenotype of p63
might come from TAp63 but not DNp63 isoforms [18], significant
controversy still exists regarding the role of individual p63 isoforms
in tumorigenesis. Decreased TAp63 levels have been linked to
poor clinical outcomes in buccal and laryngeal squamous cell
carcinomas [21,22]. TAp63 functions as a robust mediator of cell
senescence and inhibits tumorigenesis in vivo [23]. TAp63 isoforms
have been found to promote cell apoptosis through death
receptors and activating proapoptotic Bcl-2 family members
[24]. A role of TAp63 in DNA damage-induced cell cycle arrest
and cell death has also been demonstrated [25]. Conversely,
Koster et al. reported, using an inducible transgenic mouse model,
that embryonic induction of TAp63a causes keratinocyte
hyperproliferation, and inhibits terminal differentiation [26], and
that post-natal induction of TAp63a accelerates tumor develop-
ment and progression [27].
DNp63 has been reported to be over-expressed in several
different human cancers [8,12]. DNp63a is the predominant
isoform in basal keratinocytes, and its expression correlates with
proliferation in human cancers [28]. DNp63a has been shown to
promote survival in squamous epithelial malignancy by repressing
a p73-dependent proapoptotic transcriptional program [29].
However, it has also been reported that DNp63a promotes basal
keratinocyte withdrawal from the cell cycle and commitment to
terminal differentiation or apoptosis [30,31].
We have previously reported that transient overexpression of
DNp63a causes enhanced cell proliferation and inhibition of
morphological and biochemical differentiation in primary mouse
keratinocytes [20,32]. The long-term biological effects of DNp63a
and the consequences of it’s overexpression, as seen in human
squamous cell carcinomas, remain unknown. In this study we
apply a well-established model of squamous cancer to elucidate the
role of elevated levels of p63 in distinct stages of tumorigenesis. We
report that sustained elevated levels of DNp63a in normal cells
block the p16
ink4a/p19
arf pathways and promote keratinocyte
survival. However, elevated levels of DNp63a alone are insufficient
to confer a tumor phenotype in vivo. In addition to its effect on
replicative senescence, elevated DNp63a blocks oncogene-induced
senescence and associated induction of p16
ink4a/p19
arf, and
cooperates with v-ras
Ha to enhance malignant conversion in vivo.
These findings indicate an oncogenic role for the elevated levels of
DNp63a that have been observed in human squamous cell
cancers.
Results
Lentivirus infection drives long term and stable gene
expression in primary keratinocytes
To mimic the sustained high level expression of DNp63 that has
been observed in human SCC, lentiviruses encoding green
fluorescent protein (lenti-GFP) or DNp63a (lenti-DNp63a) were
developed and their ability to drive long-term gene expression was
assessed in cultures of primary epidermal keratinocytes. Under
optimized conditions, the infection efficiency as assessed with lenti-
GFP was 92.05% in primary keratinocytes five days following
lentiviral infection (Figure 1A). Lenti-DNp63a expression was
monitored over time by western blotting (Figure 1B). At five days
following infection, lenti-DNp63a levels resembled those at the
peak of adenoviral-driven gene expression (days 2–3, left panel),
and remained stable for at least 14 days (right panel). Consistent
with the FACS analysis shown for lenti-GFP in figure 1A, lenti-
DNp63a expression observed by immunohistochemistry was
distributed uniformly across the cell population (Figure 1C).
Long-term DNp63a overexpression promotes survival
and blocks replicative senescence of primary
keratinocytes
The effect of elevated levels of DNp63a on long-term in vitro
survival of primary keratinocyte cultures was assessed by
microscopic evaluation over 14 days following introduction of
lenti-GFP or lenti-DNp63a. As shown in Figure 2A, lenti-DNp63a
cultures remain confluent and appeared healthier at 14 days
compared to lenti-GFP control cultures. Proliferation status was
assessed by BrdU uptake followed by FACS analysis (Figure 2B).
The S-phase population was initially similar across the two cell
populations, as seen 5 days following introduction of the
lentiviruses (18.18% vs. 17.58% in lenti-DNp63a- vs. lenti-GFP-
expressing keratinocytes, respectively). While the S-phase popula-
tion declined in both cell populations over 2 weeks in culture, it
was maintained at higher levels in lenti-DNp63a cultures vs. the
parallel lenti-GFP control cultures (11.12% vs. 4.12% BrdU-
positive cells, respectively, at 10 days; 5.12% vs. 1.59% BrdU-
positive cells, respectively, at day 14).
The continually decreasing BrdU uptake levels in both lenti-
DNp63a and control cultures indicate that other mechanisms, in
addition to cell proliferation, are involved in the prolonged
maintenance of DNp63a overexpressing cells. Therefore, we tested
the notion that overexpression of DNp63a facilitates the capacity
of the cell to overcome replicative senescence, as originally
described by Hayflick in cultured cells [33]. A previous study by
Keyes et al., showed that inactivation of all p63 isoforms in mice
lead to cellular senescence and accelerated aging [15]. However,
the role of individual p63 isoforms in cellular senescence has
remained unclear. Here, keratinocytes were infected with lenti-
GFP or lenti-DNp63a, and the cell senescence status at day 14 was
determined by the nuclear presence of prominent HP1c-positive
senescence-associated heterochromatin foci [34]. As shown in
Figure 2C, distinct HP-1c nuclear foci were observed in control
keratinocytes that express lenti-GFP, but not in keratinocytes that
express lenti-DNp63a. Double staining with both HP-1c and p63
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associated with lower p63 expression (Figure 2C, arrows).
Senescence in most cells is regulated through some combination
of activities within the RB and p53 pathways, but frequently
operates in a context-dependent and complex manner [13]. We
examined the status of the RB and p53 pathways in keratinocytes
that differ in their senescence status due to expression of either
lenti-GFP or lenti-DNp63a. The induction of p53, p21, p16
ink4a,
p19
arf and E2F1 were examined by western blot. No induction of
p53 or p21 was observed during the timepoints studied (data not
shown). In contrast, up-regulation of p19
arf followed by p16
ink4a
was observed beginning by day 3 in control lenti-GFP keratino-
cytes cultures (Figure 3A). This expression of p16
ink4a and p19
arf
increased over time in lenti-GFP cultures, but was attenuated and
delayed in lenti-DNp63a-expressing keratinocytes (Figure 3A). As
expected, the upregulation of p16
ink4a and p19
arf correlates with
decreased levels of E2F1. The down-regulation of E2F1 was
delayed and attenuated in cells over-expressing DNp63a
Figure 1. Lentivirus infection drives long term and stable gene expression in primary keratinocytes. A, Primary mouse keratinocytes
were infected with lentivirus encoding GFP, and infection efficiency was assessed by FACS analysis at day 5 post-infection. Y-axis indicates the
intensity of GFP, X-axis represents forward angle light scatter. B, Primary keratinocytes were infected with lentivirus encoding GFP or DNp63a and
whole cell protein was collected at day 5 and 14 and analyzed for p63 expression by western blot. C, Primary keratinocyte cultures expressing lenti-
GFP or lenti-DNp63a were fixed at 14 days post-lentiviral transduction and incubated with anti-p63 antibody, followed by a secondary antibody
conjugated with Alexa-488. The cells were then stained with DAPI to visualize the cell nuclei.
doi:10.1371/journal.pone.0021877.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e21877Figure 2. Dysregulated expression of DNp63a promotes survival and blocks replicative senescence of primary keratinocytes. A,
Phase morphology of lenti-GFP- and lenti-DNp63a expressing keratinocytes cultured for 1 and 14 days post-infection. Results shown are
representative of three independent experiments. B, Quantification of BrdU positive cells in lenti-GFP or lenti-DNp63a cultures at timepoints noted
following lentiviral gene transduction. Data shown represent the means 6 S.E. of three independent experiments. * indicates a statistically significant
difference between lenti-GFP and lenti-DNp63a infected cells at p,0.05. C, Primary keratinocytes expressing lenti-GFP (left panel) or lenti-DNp63a
(right panel) were fixed at 14 days post-lentiviral transduction. The cell senescence status was assessed by the presence of HP-1c nuclear foci (red).
The cells were double stained with p63 antibodies (green). Matched arrows indicate the same cell stained with both different antibodies. The image
presented is representative of three independent experiments.
doi:10.1371/journal.pone.0021877.g002
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regulation of p16
ink4a and p19
arf by DNp63a occurs at the
transcriptional level. RT-PCR analysis on p16
ink4a and p19
arf
transcription was carried out on primary keratinocytes at day 3, 5,
7 and 10 post-lenti-GFP or lenti-DNp63a infection. As shown in
figure 3B, p16
ink4a and p19
arf mRNA began to increase in lenti-
GFP cells at day 5 post-infection. This induction was delayed in
lenti-DNp63a overexpressing cells. These findings are consistent
with a previous report, using cells null for all p63 isoforms,
demonstrating that p63 directly represses p16
Ink4a and p19
Arf
expression [35]. To further challenge the relationship between
DNp63a and p16
ink4a/p19
arf, a transient induction of DNp63a
was achieved using adenoviral-mediated gene transduction and
used to assess its impact on temporal expression of p16
ink4a/p19
arf.
Figure 3. Overexpression of DNp63a inhibits the up-regulation of p16
ink4a and p19
arf associated with cell senescence. A, Whole cell
protein was collected from primary keratinocytes expressing lenti-GFP or lenti-DNp63a at timepoints indicated following lentiviral gene transduction.
Expression levels of p16
ink4a, p19
arf, E2F1 and p63 were detected by western blot. Equal protein loading was confirmed by immunoblotting for b-
actin. B, Primary keratinocytes were infected with lentivirus encoding DNp63a or GFP at day 3 after plating. Total RNA was harvested at day 3, 5, 7 and
10 post-infection and reverse transcribed. Expression of p16
ink4a and p19
arf was determined by PCR amplification. PCR amplification of GAPDH was
used as a loading control. C, Primary keratinocytes were cultured for 7 days after plating and then infected with adenovirus encoding DNp63a or
LacZ. Whole cell lysates were collected at day 2, 3, 6 and 8 post-adenovirus infection (equivalent to day 9, 10, 13 and 15 post-plating). The expression
levels of p16
ink4a, p19
arf and p63 were detected by western blot. Equivalent protein loading was confirmed by immunoblotting for actin.
doi:10.1371/journal.pone.0021877.g003
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encoding Lac-Z or DNp63a at day 7 after plating, when p16
ink4a
and p19
arf levels normally begin to increase. The expression levels
of p16
ink4a, p19
arf and p63 were evaluated at days 2, 3, 6 and 8
after adenoviral infection (equivalent to days 9, 10, 13 and 15 after
plating, and to the time point of day 6, 7, 10 and 12 following
introduction of lentivirus in Figure 3A). As shown in Figure 3C,
adenoviral-driven gene expression of DNp63a peaked at day 2
post-infection and then rapidly declined. In control Ad-lacZ
cultures, both p16
ink4a and p19
arf levels were seen to increase 2 to
3 days following adenovirus infection, in association with the
onset of senescence typically seen in these cultures 10 days after
plating. This upregulation was abrogated in parallel cultures in
which Ad-DNp63a had been introduced. As Ad-DNp63a
levels declined, levels of both p16
ink4a and p19
arf were once again
up-regulated.
Elevated DNp63a levels enhance malignant conversion
in v-ras
Ha-expressing keratinocytes
The role of DNp63a in promoting cell proliferation and
blocking the p16
ink4a/p19
arf pathways of cell senescence, as shown
in Figures 2 and 3, indicate that DNp63a might function as an
oncogene in carcinogenesis. To determine the contribution of
DNp63a to cancer pathogenesis, we applied a well established in
vivo grafting model of experimental skin cancer that allows
distinctions between benign and malignant tumor phenotypes.
We introduced lenti-GFP or lenti-DNp63a into primary murine
keratinocytes, either alone or in combination with retrovirus
encoding a v-ras
Ha oncogene, and cultures were grafted onto the
dorsal surface of nude mice in combination with cultured dermal
fibroblasts as previously described [36]. No tumors were observed
in grafts of lenti-GFP or lenti-DNp63a keratinocytes following
grafting (Figure 4A and Table 1). Graft sites on 4 of the 15 animals
that received lenti-GFP/v-ras
Ha-expressing keratinocytes devel-
oped benign, well-differentiated papillomas with an average tumor
volume of 25 mm
3. In contrast, when v-ras
Ha was expressed in
combination with lenti-DNp63a, all grafts (20 mice) gave rise to
undifferentiated carcinomas with an average tumor volume of
831.9 mm
3 (figure 4A, B and Table 1). The increased tumor size
corresponded to increased BrdU incorporation, as detected by
immunohistochemistry (Figure 4B and C), reflecting a higher
proliferation status in these tumors.
Long term DNp63a overexpression blocks oncogene-
induced senescence and supports long term survival of
v-ras
Ha-expressing primary keratinocytes
It has been well documented that normal keratinocytes undergo
a transient hyperproliferation response followed by senescence
after oncogenic v-ras
Ha activation [37]. Oncogene-induced
senescence is now well appreciated to be a crucial barrier to
malignant conversion [13]. The above results (Figure 4) demon-
strate that elevated DNp63a levels enhance malignant conversion
in v-ras
Ha-expressing keratinocytes and suggest that DNp63a may
play a role in blocking oncogene-induced senescence as well as
replicative senescence. Primary keratinocytes were transduced
with retrovirus encoding oncogenic v-ras
Ha followed by lentivirus
encoding either lenti-GFP (Figure 5A, left) or lenti-DNp63a
(Figure 5A, right). Oncogene-induced senescence was demonstrat-
ed at day 14 with the presence of nuclear foci of HP-1c (Figure 5A,
upper panels) or SA-b-Gal staining (Figure 5A, lower panels).
While both of these well-defined markers of senescence were
observed in lenti-GFP/v-ras
Ha cultures, they were diminished in
lenti-DNp63a/v-ras
Ha keratinocytes.
p53 has been shown to direct cell fate between quiescence vs.
senescence, and this has been linked to the status of the mTOR
pathway [38,39]. We evaluated levels of phospho-S6 as a marker of
mTOR activity in v-ras
Ha-expressing primary keratinocytes that
had been transduced with either lenti-GFP or lenti-DNp63a.N o
changewas observed inphospho-S6 levelsduetothe DNp63astatus
at days 5, 7 and 14 post-lentiviral infection, the timeframe during
which control cultures are transitioning through senescence. These
findings indicate that suppression of senescence in this system is not
mediated via inhibition of mTOR (data not shown).
Similar to results seen with keratinocytes undergoing replicative
senescence (Figure 3A), western blotting revealed up-regulation of
both p16
ink4a and p19
arf in the presence of v-ras
Ha (lenti-GFP/v-
ras
Ha) that was attenuated and delayed in the additional presence
of elevated DNp63a (Figure 5B). Furthermore, consistent with the
increased proliferation status observed in tumors generated from
lenti-DNp63a/v-ras
Ha keratinocytes (Figure 4B and C), the levels
of E2F1 and phosphorylated AKT (serine 473) remain stable in
lenti-DNp63a/v-ras
Ha keratinocytes, but start to decrease at day 7
in lenti-GFP/v-ras
Ha keratinocytes (Figure 5B).
We have shown that sustained dysregulation of DNp63a in
keratinocytes supports cell proliferation and facilitates an escape
from oncogene-induced senescence (Figure 5A and B). We tested
whether co-expression of DNp63a and v-ras
Ha would cooperate to
immortalize cells and allow multiple passaging of primary mouse
keratinocytes. Primary cultures of v-ras
Ha-expressing keratinocytes
were transduced with lentiviruses encoding lenti-GFP or lenti-
DNp63a. The cells were trypsinized 14 days following lentivirus
introduction and reseeded. As shown in Figure 6A, lenti-GFP/v-
ras
Ha keratinocytes display a senescence-like morphology 3 days
after replating that is not observed in lenti-DNp63a/v-ras
Ha
keratinocytes. Furthermore, lenti-DNp63a/v-ras
Ha keratinocytes
re-attached and expanded for at least two passages, whereas lenti-
GFP/v-ras
Ha keratinocytes stopped proliferation after the initial
reseeding (Figure 6B).
Loss of p19
arf cooperates with v-ras
Ha in malignant
conversion, similar to lenti-DNp63a-expressing
keratinocytes
To determine whether DNp63a-mediated downregulation of
p16
ink4a or p19
arf could enhance malignant conversion, p19
arf-null
primary keratinocytes were transduced with v-ras
Ha-encoding
retrovirus, followed by lenti-GFP or lenti-DNp63a and grafted
onto the dorsal surface of nude mice as previously described [36].
Wildtype primary keratinocytes expressing lenti-GFP or lenti-
DNp63a in combination with v-ras
Ha were used as negative and
positive controls. Out of 10 animals grafted with p19
arf-null
keratinocytes expressing lenti-GFP and v-ras
Ha, 9 animals gave
rise to undifferentiated carcinomas, which appeared similar to the
tumor phenotype derived from keratinocytes overexpressing
DNp63a. The remaining animal developed a well differentiated
papilloma (Figure 7A and B, Table 2). A significantly larger tumor
volume was observed in tumors derived from lenti-DNp63a/v-
ras
Ha-expressing p19
arf-null keratinocytes when compared to
tumors derived from p19
arf-null cells that express v-ras
Ha alone
(Figure 7B).
Discussion
Expression of DNp63a is associated with proliferation of both
normal and neoplastic epithelium, with elevated levels observed in
human squamous cancer tissues [1,8–12]. Here, we provide a
mechanistic link between the elevated levels of DNp63a and
development of squamous cell cancers. The grafting model applied
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and allows the discrimination of genetic alterations that contribute
to distinct stages of cancer development. We demonstrate that
DNp63a overexpression alone does not confer a neoplastic
phenotype upon normal primary keratinocytes under the condi-
tions used, but enhances malignant conversion of benign tumors
arising from primary murine keratinocytes that express oncogenic
ras. This phenotypic change appears to be due, at least in part, to
the ability of DNp63a to enhance cell survival through suppression
of p16
ink4a/p19
arf, key mediators of cell senescence.
Figure 4. Elevated expression of DNp63a enhances malignant conversion in v-ras
Ha-expressing keratinocytes. A, In vivo phenotype of
DNp63a-overexpressing keratinocytes in the presence and absence of oncogenic ras. Primary mouse keratinocytes were infected with lentivirus
encoding lenti-GFP or lenti-DNp63a or sequentially with retrovirus encoding v-ras
Ha followed by lenti-GFP or lenti-DNp63a. The final tumor
phenotype was assessed at 5 weeks following grafting. Final tumor volumes at 4 weeks are presented as the mean tumor volume 6 S.E. B, Upper
panel, representative H&E sections of tumor tissues obtained from grafting sites. Lower panel, BrdU incorporation in grafted tissue samples. C,
Quantification of BrdU incorporation levels. Data are presented as the mean % of BrdU positive cells 6 S.E. * indicates a statistically significant
difference between lenti-GFP/v-ras
Ha and lenti-DNp63a/v-ras
Ha groups at p,0.05.
doi:10.1371/journal.pone.0021877.g004
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growth arrest in cultured human cells [33]. It is now understood
that it can be prematurely induced by multiple stimuli including
DNA damage, oxidative stress, and excessive mitogenic stimuli
[40], [41], and represents a potent anticancer mechanism to
prevent malignant conversion [14]. The complexities of the
signaling pathways mediating the senescence response, and the
dependence of this response on p53, are underscored by the
contrasting results observed in vitro and in vivo in keratinocytes
undergoing senescence induced by p63 ablation [15].
The inhibition of cell senescence by DNp63a is linked to its
ability to repress the expression of p16
ink4a and p19
arf (Figure 5).
While p16
ink4a and p19
arf play well-defined roles in controlling cell
cycle and senescence, their regulation remains poorly understood.
Our finding that DNp63a negatively regulates p16
ink4a and p19
arf
in primary mouse keratinocytes is consistent with recent studies
linking p63 to cellular senescence and organismal aging, in which
keratinocytes of p63-deficient mice display increased levels of
p16
ink4a/p19
arf [15]. The ability of p63 to bind putative p53/p63
consensus sites on the p16
ink4a/p19
arf promoters, as demonstrated
by ChIP analysis using cells null for all isoforms of p63, raises the
possibility that p63 acts as a direct repressor of the p16
ink4a/p19
arf
locus. A function for p16
ink4a downstream of p63 is also supported
by the observation that germline disruption of both p16
ink4a and
p19
arf was found to significantly alleviate the phenotypic
consequences of p63 ablation during embryonic epidermal
development [35]. Despite the above studies, the relationship
between DNp63a and p16
ink4a in cancer remains unclear.
Consistent with the findings reported here, a recent study by
Keyes et al. [2] demonstrated that overexpression of DNp63a
bypasses oncogenic ras-induced senescence and drives tumorigen-
eisis in vivo. However, in contrast to our results, Keyes et al.
reported that the level of p16
ink4a remains stable in oncogenic ras
and DNp63a expressing cells, and concluded that the inhibition of
senescence by DNp63a occurs via an additional pathway, but not
through modulating p16
ink4a. This indicates the complexity of the
pathways interacting with p63 family members, and underscores
the need for additional studies to understand the role of p63 and its
downstream effectors in tumorigenesis and senescence.
p63 is recognized as a regulator of epidermal cell fate and lineage
commitment [42,43]. The pathways involved in regulating
epidermal development as well as homeostasis and differentiation
of postnatal keratinocytes continue to be targets of active
investigation [6,28,44]. Much effort has focused on the identifica-
tion of downstream pathways of DNp63a contributing to neoplasia,
including NFkB/c-Rel, EGF-R and COX-2 [45–47]. Furthermore,
the ability of DNp63a to inhibit transcriptional regulatory activity of
other p53 family members may contribute to a loss of genomic
stability that could enhance progression to malignancy [1]. Our
laboratory has previously demonstrated that NFkB/c-Rel mediates
the aberrant growth regulationobserved in DNp63a-overexpressing
keratinocytes [43]. Here, we establish that the ability of DNp63a to
overcome senescence and drive malignancy is linked to its
downregulation of the p16
ink4a/p19
arf pathways. As proof of
principle that the loss of p16
ink4a/p19
arf can contribute to
DNp63a-induced malignant conversion, an in vivo grafting study
showed that, similar to lenti-DNp63a-expressing keratinocytes,
p19
arf null keratinocytes formed malignant carcinomas in the
presence of v-ras
Ha (Figure 7). However, a significantly larger tumor
volume was observed in tumors derived from lenti-DNp63a/v-
ras
Ha-expressingp19
arfnullkeratinocyteswhen comparedtotumors
derived from p19
arf null cells expressing v-ras
Ha alone (Figure 7B).
Our results suggest that additional mechanisms, e.g. p16
ink4a or c-
Rel, contribute to DNp63a -induced malignant tumor formation
[45]. Future studies are required to dissect the relative roles of each
individual downstream pathway influenced by p63 and their
cooperative contribution to discrete steps of cancer pathogenesis.
Materials and Methods
Ethics Statement
All animal work was performed in accordance with NIH
(National Institutes of Health) established guidelines, in accor-
dance with accepted standards of humane animal care under
protocols approved by the Animal Care and Use Committee of the
Center for Biologics Evaluation and Research of the Food and
Drug Administration.
Cell Culture
Primary keratinocytes and dermal fibroblasts were isolated from
the skin of 1–2 day-old C57B1/6NCr mice, cultured and plated as
described [20]. Keratinocytes were maintained at a final
concentration of 0.05 mM Ca
2+. Fibroblasts were cultured for 9
days in DMEM prior to use in grafting studies.
Adenovirus encoding DNp63a has been previously described
[20]. The replication-defective Psi-2 retroviral vector encoding v-
ras
Ha was used to introduce a v-ras
Ha oncogene at day-2 post-
plating as previously described [36]. The infection of adenovirus
encoding Lac-Z or DNp63a was performed as previously
described [20].
Lentivirus construction and infection
Lentivirus encoding human DNp63a was generated by ligating
the complete coding region of DNp63a cDNA excised from
pBMNiGFP–human DNp63a plasmid into lentiviral expression
vector 960-X5-685 (pSICO-FerH-eGFP). The constructed
pSICO-hFerH-human DNp63a was verified via restriction enzyme
mapping and sequencing analysis. A similarly constructed
lentiviral vector encoding GFP was used as a matched control.
Lentiviruses were produced in HEK293T cells (Open Biosystems,
Huntsville, AL). The producer cells were washed and incubated
with standard keratinocyte medium 24 hours before harvesting
(SAIC, Inc., Frederick, MD).
Keratinocytes, 3 days post-plating, were incubated for 3 hours
in lentivirus-containing supernatant and 4 mg/mL polybrene
(500 ml/60 mm
2 dish). Fresh medium was added at the end of
the incubation. The induction of lenti-DNp63a was evaluated by
western blot and immunofluorescent staining.
In vivo grafting and tumor sample collection
Keratinocyte cultures were infected with retrovirus encoding v-
ras
Ha one day prior to infection with lentivirus encoding either
Table 1. Elevated DNp63a levels enhance malignant
conversion in v-ras
Ha-expressing keratinocytes.
Normal
Skin Papilloma Carcinoma Total
Conversion
rate
Lenti-GFP 10 0 0 10 0%
Lenti-DNp63a 10 0 0 10 0%
Lenti-GFP/v-ras
Ha 11 (73.3%) 4 (26.7%) 0 15 0%
Lenti-DNp63a/
v-ras
Ha
0 0 20 (100%) 20 100%
Tumor incidence and conversion rate of grafted keratinocytes are presented at
5 weeks post-grafting. Tumor phenotypes were confirmed histologically.
doi:10.1371/journal.pone.0021877.t001
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infection and 4610
6 keratinocytes were mixed with 8610
6
cultured dermal cells and transferred to a grafting chamber
freshly implanted onto the dorsum of a nude mouse [36,48]. The
chamber was removed 1 week following grafting. Tumor volume
was measured every 3 days following the initial appearance of a
tumor. Mice were injected with 250 ml of 50 mM 5-bromo-29-
deoxyuridine (BrdU, Sigma Chemical, St. Louis, MO) 1 hour
prior to euthanasia and tumor harvest to allow immunohisto-
chemical analysis of DNA synthesis in the grafted cells. Tumor
tissues were collected 4 weeks after removing the chambers and
fixed in formalin-buffered saline.
Figure 5. Long term DNp63a overexpression blocks oncogene-induced senescence. A, Primary keratinocytes were infected sequentially
with retrovirus encoding oncogenic v-ras
Ha, followed by lentivirus encoding GFP or DNp63a. Oncogene-induced senescence was assessed 14 days
post-lentivirus infection by immunofluorescent analysis of nuclear foci of HP-1c (upper panel), or enzymatic activity of SA-b-gal (lower panel). The
images shown are representative of three independent experiments. B, Whole cell protein was collected from keratinocytes infected sequentially with
retrovirus encoding oncogenic v-ras
Ha followed by lentivirus encoding GFP or DNp63a at timepoints indicated following lentiviral gene transduction.
The levels of phosphorylated AKT, total AKT, p19
arf and p63 were detected by western blot (upper panels). p16
ink4a and E2F1 levels with
corresponding p63 expression are presented in the lower panels. Equal protein loading was confirmed by immunoblotting for b-actin.
doi:10.1371/journal.pone.0021877.g005
Oncogenic Activity of DNp63a in Skin Tumorigenesis
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e21877BrdU incorporation
BrdU incorporation in the grafted tissue sample was detected by
immunohistochemical staining using an antibody against BrdU
(B44, BD Biosciences, San Jose, CA) and tissues were counter-
stained with Contrast Green (KPL, Inc., Gaithersburg, MD). At
least 100 basal cells were scored for each sample; in the case of
undifferentiated carcinomas 100 cells/field were counted. BrdU
incorporation in vitro was detected by Fluorescent Activated Cell
Sorting (FACS) analysis as previously described [32].
Senescence assays
For HP1c detection, culture dishes were fixed with methanol at
220uC and incubated with antibody directed to HP1c
(MAB3450, Chemicon International, Billerica, MA), and p63
(4A4, Santa Cruz Biotechnology, Santa Cruz, CA). Cells were
then incubated with a FITC- or rhodamine-labeled secondary
antibody (Invitrogen) and viewed under a fluorescence micro-
scope. Senescence-associated b-galactosidase (SA-b-gal) staining
was performed as previously described [36].
Figure 6. Overexpression of DNp63a supports long term survival of v-ras
Ha-expressing primary keratinocytes. Primary keratinocytes
were infected sequentially with retrovirus encoding oncogenic v-ras
Ha and lentivirus encoding GFP or DNp63a, as noted. On post-infection day 14,
the cells were trypsinized and reseeded. A, cell morphology was recorded at day 3 after the initial reseeding. B, growth curves of keratinocytes
expressing v-ras
Ha in conjunction with lenti-GFP or lenti-DNp63a. Cell numbers were counted at days 1, 3, 7, 10 and 14 post-lentivirus infection
(passage 0), or at the same timepoints following each reseeding. Data are expressed as cell number per well and represent the means 6 S.D. of two
independent experiments.
doi:10.1371/journal.pone.0021877.g006
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Keratinocytes were infected with retrovirus encoding v-ras
Ha,
followed by lenti-DNp63a or lenti-GFP. Cells were collected by
trypsinization and counted using a hemocytometer (Hausser
Scientific, Horsham, PA) at timepoints noted. At 14 days post-
infection, the cultures were trypsinized and reseeded at 0.5610
5
cells per well, then counted as above at timepoints noted.
Immunoblot Analysis
Immunoblot analysis was performed using standard procedures.
The following primary antibodies were used: p63 (4A4, Santa
Cruz Biotechnology), E2F1 (C-20, Santa Cruz Biotechnology),
p16 (M-156, Santa Cruz Biotechnology), p19 (5-C3-1, Santa Cruz
Biotechnology), b-actin (Clone AC-15, Sigma Chemical), phos-
pho-AKT (ser473) (D9E, Cell Signaling Technology, Boston,
MA), AKT (pan) (C67E7, Cell Signaling Technology) and
phospho-S6 (Ser235/236) (D27.2.2E) and S6 (5G10) (Cell
signaling Technology).
RNA isolation and Reverse Transcription-PCR
Total RNA was harvested using TRIzol reagent (Invitrogen)
and reverse transcribed (1 mg) using the SuperScript III first strand
Figure7. v-ras
Ha-expressingp19
arf nullkeratinocytes displayatumorphenotypesimilar tov-ras
Ha/DNp63aoverexpressing keratinocytes.
A,p19
arf null primary keratinocytes wereinfected withlenti-GFP or lenti-DNp63ain combination withv-ras
Ha,and grafted onto the dorsal side of nude miceas
previously described [36]. Wild type primary keratinocytes expressing lenti-GFP or lenti-DNp63a in combination with v-ras
Ha were used as negative and
positive controls. The final tumor phenotype was assessed at 5 weeks after grafting. B, Final tumor volumes at 5 weeks are presented as the mean tumor
volume 6 S.E. * indicates a statistically significant difference between p19
arf null/v-ras
Ha and p19
arf null/lenti-DNp63a/v-ras
Ha groups at p,0.05.
doi:10.1371/journal.pone.0021877.g007
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Expression of p16 and p19 mRNA was determined by PCR
amplification using primers specific for the mouse p16/p19 gene
(p16: sense 59-GCTGCAGACAGACTGGCCA-39; antisense 59-
GTCCTCGCAGTTCGAATCTG-39) [49]. p19: sense 59-
GTCGCAGGTTCTTGGTCACT-39; antisense 59-ATGTT-
CACGAAAGCCAGAGC-39) [50]. PCR amplification of
GAPDH was used as a loading control. The PCR reaction
program was as follows: denaturation, 94uC, 30 s; annealing,
53uC, 30 s; elongation, 72uC, 30 s for 35 cycles.
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